Get the Stockscreener App
197.37
1.47%
2.85
After Hours:
197.37
Natera Inc stock is traded at $197.37, with a volume of 665.49K.
It is up +1.47% in the last 24 hours and down -6.83% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$194.52
Open:
$196.4
24h Volume:
665.49K
Relative Volume:
0.57
Market Cap:
$27.97B
Revenue:
$2.31B
Net Income/Loss:
$-208.16M
P/E Ratio:
-128.45
EPS:
-1.5366
Net Cash Flow:
$76.11M
1W Performance:
-0.21%
1M Performance:
-6.83%
6M Performance:
+20.60%
1Y Performance:
+27.68%
1-Day Range:
$195.78
$202.88
1-Week Range:
$191.50
$204.34
52-Week Range:
$125.38
$256.36
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
197.37 | 27.57B | 2.31B | -208.16M | 76.11M | -1.5366 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.14B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 134.43B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.40B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 32.27B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Natera (NTRA) Launches Zenith Genomic Assay - Insider Monkey
Natera, Inc. (NASDAQ:NTRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Natera Inc (NTRA) Stock Price Up 2.86% on Mar 23 - GuruFocus
Natera, Inc.(NasdaqGS: NTRA) added to FTSE All-World Index - marketscreener.com
Natera co-founder Jonathan Sheena sells shares worth $908,301 By Investing.com - Investing.com Canada
Natera co-founder Jonathan Sheena sells shares worth $908,301 - Investing.com UK
Natera Inc (NTRA) Shares Gap Down to $196.73 on Mar 20 - GuruFocus
Natera (NASDAQ: NTRA) co-founder reports 4,570-share planned stock sale - Stock Titan
Form 144 Natera For: 20 March By Investing.com - Investing.com South Africa
Form 144 Natera For: 20 March - Investing.com
Jonathan Sheena reports multiple share sales for NTRA (NASDAQ: NTRA) - Stock Titan
Discipline and Rules-Based Execution in NTRA Response - Stock Traders Daily
Natera's 87.71% Trading Volume Spike Pushes 475th Market Rank as Shares Fall 3.67% Amid Earnings Optimism and Insider Selling - Bitget
CIBC Private Wealth Group LLC Buys 53,086 Shares of Natera, Inc. $NTRA - MarketBeat
Does Natera’s (NTRA) Expanded Genomics Suite Quietly Redefine Its Long-Term Competitive Moat? - simplywall.st
Groupama Asset Managment Has $12.42 Million Stock Holdings in Natera, Inc. $NTRA - MarketBeat
Unveiling Natera (NTRA) Q4 outlook: Wall Street estimates for key metrics - MSN
Jonathan Sheena files Rule 144 notice selling shares (NASDAQ: NTRA) - Stock Titan
Natera, Inc. (NTRA) reports preliminary Q4 revenue - MSN
Faithward Advisors LLC Invests $3.52 Million in Natera, Inc. $NTRA - MarketBeat
Livforsakringsbolaget Skandia Omsesidigt Buys 17,100 Shares of Natera, Inc. $NTRA - MarketBeat
JP Morgan lifts Natera, Inc. (NTRA) target on Signatera momentum - MSN
Insider Selling: Natera (NASDAQ:NTRA) Director Sells 122 Shares of Stock - MarketBeat
Natera director Chapman sells $23348 in shares - Investing.com
Natera director Chapman sells $23348 in shares By Investing.com - Investing.com Australia
Natera (NTRA) director sells 122 shares under 10b5-1 trading plan - Stock Titan
Natera Looks Compelling As Oncology Testing Momentum Keeps Building (NASDAQ:NTRA) - Seeking Alpha
Natera named Healthcare Technology Company of the Year - The Healthcare Technology Report.
A Look At Natera (NTRA) Valuation After New Signatera Data And Zenith Genomics Launch - Yahoo Finance
Assessing Natera (NTRA) Valuation After New Signatera Data And Zenith Genomics Launch - simplywall.st
Holocene Advisors LP Decreases Stock Holdings in Natera, Inc. $NTRA - MarketBeat
Boothbay Fund Management LLC Increases Position in Natera, Inc. $NTRA - MarketBeat
Natera executive chairman sells $38.3 million in NTRA stock - Investing.com
Natera executive chairman sells $38.3 million in NTRA stock By Investing.com - Investing.com South Africa
NeoGenomics, Natera, and Amphastar Pharmaceuticals Stocks Soar—Key Information You Should Be Aware Of - Bitget
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know - Yahoo Finance
Natera (NTRA) chair Rabinowitz exercises options and sells 200,000 shares - Stock Titan
NeoGenomics, Natera, and Amphastar Pharmaceuticals shares skyrocket, what you need to know - MSN
Why Natera Stock Is Surging On Fresh Optimism - TipRanks
NTRA Debuts Zenith Genomics Next-Gen Sequencing Test for Rare Diseases - Yahoo Finance
Natera (NTRA) Highlights Promising Results for Signatera in Canc - GuruFocus
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers - BioSpace
Natera ctDNA test shows promise in anal, rectal cancer studies - Investing.com
Natera ctDNA test shows promise in anal, rectal cancer studies By Investing.com - Investing.com India
Fred Alger Management LLC Buys 41,303 Shares of Natera, Inc. $NTRA - MarketBeat
Farallon Capital Management LLC Sells 568,357 Shares of Natera, Inc. $NTRA - MarketBeat
Cancer DNA test ties anal and rectal tumors to relapse odds - Stock Titan
Natera launches whole genome sequencing test for rare diseases - Investing.com Nigeria
Coatue Management LLC Takes Position in Natera, Inc. $NTRA - MarketBeat
Capital Impact Advisors LLC Boosts Stock Position in Natera, Inc. $NTRA - MarketBeat
Aquatic Capital Management LLC Increases Position in Natera, Inc. $NTRA - MarketBeat
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):